OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press2510.17650/1818-8346-2013-8-3-42-47HEMATOPOIETIC STEM CELL TRANSPLANTATIONТРАНСПЛАНТАЦИЯ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК У ПАЦИЕНТОВ С ГЕМОБЛАСТОЗАМИFeatures of transfusion therapy in patients undergoing hematopoietic stem cell transplantation. Review of the literatureОсобенности проведения трансфузионной терапии у пациентов после трансплантации гемопоэтических стволовых клеток. Обзор литературыBalashovD. N.БалашовД. Н.
Russian Federation
bala8@yandex.ruTrakhtmanP. E.ТрахтманП. Е.
Russian Federation
Dmitriy Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of RussiaФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава России2108201383424721072014210720142013https://oncohematology.abvpress.ru/ongm/article/view/25

The indications for transfusion of blood components support after stem cell transplantation (SCT) usually do not differ form other clinical situations, but the rules for such therapy have a number of features. One of them is the possibility of inconsistence of AB0 group between donor and recipient of hematopoietic stem cells, which is not only fraught with the development of various alloimmune complications, but also fundamentally changes the standards for the selection of blood components for transfusion. A major problem after HSCT is a secondary immunodeficiency, which is important to consider for ensuring prevention of transfusion-transmitted infections (eg, CMV), as well as to carry out activities aimed for the prevention of transfusion- associated graft-versus-host disease. HSCT is a medical technology today, the effectiveness of which is often dependent on the accuracy and integrity of its implementation. So, serious attitude to various supportive therapy, including transfusions of blood components is an important component which determines the success of the treatment.

hemopoietic stem cell transplantationtransfusion therapy,hemolysisalloimmunizationtransfusion-associated graft-versushost diseaseтрансплантация гемопоэтических стволовых клетоктрансфузионная терапиягемолизаллоиммунизациятрансфузионно-ассоциированная реакция «трансплантат против хозяина»1. Worel N., Greinix H.T., Schneider B. et al. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion 2000;40(5):543–50.Worel N., Greinix H.T., Schneider B. et al. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion 2000;40(5):543–50.2. Maciej Zaucha J., Mielcarek M., Takatu A. et al. Engraftment of early erythroid progenitors is not delayed after nonmyeloablative major ABO-incompatible hematopoietic stem cell transplantation. Br J Haematol 2002;119:740–50.Maciej Zaucha J., Mielcarek M., Takatu A. et al. Engraftment of early erythroid progenitors is not delayed after nonmyeloablative major ABO-incompatible hematopoietic stem cell transplantation. Br J Haematol 2002;119:740–50.3. Bolan C.D., Childs R.W., Procter J.L. et al. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haematol 2001;112:787.Bolan C.D., Childs R.W., Procter J.L. et al. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haematol 2001;112:787.4. Tomonari A., Takahashi S., Ooi J. et al. Impact of ABO incompatibility on engraftment and transfusion requirement after unrelated cord blood transplantation: a single institute experience in Japan. Bone Marrow Transplant 2007;40(6):523–8.Tomonari A., Takahashi S., Ooi J. et al. Impact of ABO incompatibility on engraftment and transfusion requirement after unrelated cord blood transplantation: a single institute experience in Japan. Bone Marrow Transplant 2007;40(6):523–8.5. Snell M., Chau C., Hendrix D. et al. Lack of isohemagglutinin production following minor ABO incompatible unrelated HLA mismatched umbilical cord blood transplantation. Bone Marrow Transplant 2006;38(2):135–40.Snell M., Chau C., Hendrix D. et al. Lack of isohemagglutinin production following minor ABO incompatible unrelated HLA mismatched umbilical cord blood transplantation. Bone Marrow Transplant 2006;38(2):135–40.6. Gajewski J.L., Johnson V.V., Sandler S.G. et al. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood 2008;112(8):3036–47.Gajewski J.L., Johnson V.V., Sandler S.G. et al. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood 2008;112(8):3036–47.7. Schiffer C.A., Anderson K.C., Bennett C.L. et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 200;19(5):1519–38.Schiffer C.A., Anderson K.C., Bennett C.L. et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 200;19(5):1519–38.8. Gil-Fernández J.J., Alegre A., Fernández-Villalta M.J. et al. Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant 1996;18(5):931–5.Gil-Fernández J.J., Alegre A., Fernández-Villalta M.J. et al. Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant 1996;18(5):931–5.9. Bernstein S.H., Nademanee A.P., Vose J.M. et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 1998;91(9):3509–17.Bernstein S.H., Nademanee A.P., Vose J.M. et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 1998;91(9):3509–17.10. Nevo S., Enger C., Hartley E. et al. Acute bleeding and thrombocytopenia after bone marrow transplantation. Bone Marrow Transplant 2001;27(1):65–72.Nevo S., Enger C., Hartley E. et al. Acute bleeding and thrombocytopenia after bone marrow transplantation. Bone Marrow Transplant 2001;27(1):65–72.11. Barge A.J., Johnson G., Witherspoon R., Torok-Storb B. Antibody-mediated marrow failure after allogeneic bone marrow transplantation. Blood 1989;74(5):1477–80.Barge A.J., Johnson G., Witherspoon R., Torok-Storb B. Antibody-mediated marrow failure after allogeneic bone marrow transplantation. Blood 1989;74(5):1477–80.12. Claas F.H., Smeenk R.J., Schmidt R. et al. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp Hematol 1981;9(1):84–9.Claas F.H., Smeenk R.J., Schmidt R. et al. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp Hematol 1981;9(1):84–9.13. Welsh K.I., Burgos H., Batchelor J.R. The immune response to allogeneic rat platelets; Ag-B antigens in matrix form lacking Ia. Eur J Immunol 1977;7(5):267–72.Welsh K.I., Burgos H., Batchelor J.R. The immune response to allogeneic rat platelets; Ag-B antigens in matrix form lacking Ia. Eur J Immunol 1977;7(5):267–72.14. Oksanen K., Kekomäki R., Ruutu T. et al. Prevention of alloimmunization in patients with acute leukemia by use of white cellreduced blood components – a randomized trial. Transfusion 1991;31(7):588–94.Oksanen K., Kekomäki R., Ruutu T. et al. Prevention of alloimmunization in patients with acute leukemia by use of white cellreduced blood components – a randomized trial. Transfusion 1991;31(7):588–94.15. Saarinen U.M., Kekomäki R., Siimes M.A., Myllylä G. Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components. Blood 1990;75(2):512–7.Saarinen U.M., Kekomäki R., Siimes M.A., Myllylä G. Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components. Blood 1990;75(2):512–7.16. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337(26):1861–9.The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337(26):1861–9.17. Friedberg R.C., Donnelly S.F., Boyd J.C. et al. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 1993;81(12):3428–34.Friedberg R.C., Donnelly S.F., Boyd J.C. et al. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 1993;81(12):3428–34.18. Bowden R.A., Sayers M., Gleaves C.A. et al. Cytomegalovirus-seronegative blood components for the prevention of primary cytomegalovirus infection after marrow transplantation. Considerations for blood banks. Transfusion 1987;27(6):478–81.Bowden R.A., Sayers M., Gleaves C.A. et al. Cytomegalovirus-seronegative blood components for the prevention of primary cytomegalovirus infection after marrow transplantation. Considerations for blood banks. Transfusion 1987;27(6):478–81.19. Pamphilon D.H., Rider J.R., Barbara J.A., Williamson L.M. Prevention of transfusiontransmitted cytomegalovirus infection. Transfus Med 1999;9(2):115–23.Pamphilon D.H., Rider J.R., Barbara J.A., Williamson L.M. Prevention of transfusiontransmitted cytomegalovirus infection. Transfus Med 1999;9(2):115–23.20. Narvios A.B., de Lima M., Shah H., Lichtiger B. Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients. Bone Marrow Transplant 2005;36(6):499–501.Narvios A.B., de Lima M., Shah H., Lichtiger B. Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients. Bone Marrow Transplant 2005;36(6):499–501.21. FDA memorandum to registered blood establishments: Recommendations regarding license amendments and procedures for gamma irradiation of blood products. (http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/otherrecommendationsformanufacturers/memorandumtobloodestablishments/default. htm).FDA memorandum to registered blood establishments: Recommendations regarding license amendments and procedures for gamma irradiation of blood products. (http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/otherrecommendationsformanufacturers/memorandumtobloodestablishments/default. htm).